RedHill Biopharma
CompanyIsrael
RedHill Biopharma develops one asset, in phase 2 (Opaganib in cholangiocarcinoma). Mostly small molecule acting on SPHK2; based in Israel.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $128M
- 3
- Trials
- 2
- Signals
Pipeline
1Inhibits sphingosine kinase 2, disrupting sphingolipid signaling and promoting cancer cell apoptosis.
Phase 2, Small molecule, SPHK2, cholangiocarcinoma, cholangiocarcinoma non resectable
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials3
- Funding rounds and grants7
- People12
- Signals4
- Similar companies6